Bio-similars, neoterics of pharmaceuticals

3^rd International Conference and Exhibition on Biowaivers, Biologics & Biosimilars

October 27-29, 2014 Hyderabad International Convention Centre, Hyderabad, India

Kalakonda Sri Nataraj

Accepted Abstracts: J Bioanal Biomed

Abstract :

Pharmaceutical industry has always been the most bread neck for transformation in the field of research and healthcare. The evolution of medicines from the traditional leaf extracts to swinging Liposome's, human insulin preparations, delayed release and modified release formulations & multilayered multi tablets is promising and riveting. However, growing aging population, chronic diseases around the globe and synchronic rise in the demand for spanking quality in healthcare has brought the need to develop products called Biosimilars. Biosimilars are on the whole a new class of biologic drugs which are similar to the generics but not identical. They are state of art designer molecules derived from living organisms. WHO defines Biosimilars as ?A bio therapeutic product which is similar in terms of quality, safety and efficacy to an already licensed reference bio therapeutic product?. Over the next few years, generic drugs worth an estimated $81 billion in global annual sales, and biologics worth 20 billion $ will lose their patents by 2015. Globally Biosimilars market is predicted to grow by US $19.4 billion in 2014. By then, fusion proteins and monoclonal antibodies used in cancer and autoimmune diseases are expected to form a substantial proportion of this new line of biosimilars. Biosimilars are advantageous over biologics in saving costs and expenditures on the whole lot of departments like developing, manufacturing, analytical testing and marketing of the products. Regulatory agencies like WHO, USFDA and EMA are developing laws and standards to develop spanking quality of products to the healthcare world. The transformation from biologics to biosimilars is going to dawn a new generation of medicines using advanced techniques in the field of treatments. India and south central Asia are going to be the hub for this new generation neoterics in pharmaceuticals.

Biography :

Kalakonda Sri Nataraj has completed his PhD at the age of 35 years from JNTUA University. He is the Professor of Shri Vishnu College of Pharmacy, accredited by NBA & NAAC. He has published more than 32 papers in reputed journals and serving as an Editorial Board Member of repute and recently sanctioned the project from DST under young scientist scheme.